Tikvah K Hayes
Tikvah K Hayes
1Department of Medical Oncology, Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA USA
2Cancer Program, The Broad Institute of M.I.T. and Harvard, Cambridge, MA USA
10Present Address: Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA USA
1,2,10,
Elisa Aquilanti
Elisa Aquilanti
1Department of Medical Oncology, Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA USA
2Cancer Program, The Broad Institute of M.I.T. and Harvard, Cambridge, MA USA
1,2,
Nicole S Persky
Nicole S Persky
2Cancer Program, The Broad Institute of M.I.T. and Harvard, Cambridge, MA USA
3Genetic Perturbation Platform, The Broad Institute of M.I.T. and Harvard, Cambridge, MA USA
11Present Address: Aera Therapeutics, Cambridge, MA USA
2,3,11,
Xiaoping Yang
Xiaoping Yang
3Genetic Perturbation Platform, The Broad Institute of M.I.T. and Harvard, Cambridge, MA USA
3,
Erica E Kim
Erica E Kim
1Department of Medical Oncology, Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA USA
1,
Lisa Brenan
Lisa Brenan
2Cancer Program, The Broad Institute of M.I.T. and Harvard, Cambridge, MA USA
2,
Amy B Goodale
Amy B Goodale
3Genetic Perturbation Platform, The Broad Institute of M.I.T. and Harvard, Cambridge, MA USA
3,
Douglas Alan
Douglas Alan
3Genetic Perturbation Platform, The Broad Institute of M.I.T. and Harvard, Cambridge, MA USA
3,
Ted Sharpe
Ted Sharpe
4Data Science Platform, The Broad Institute of M.I.T. and Harvard Cambridge, Cambridge, MA USA
4,
Robert E Shue
Robert E Shue
1Department of Medical Oncology, Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA USA
2Cancer Program, The Broad Institute of M.I.T. and Harvard, Cambridge, MA USA
1,2,
Lindsay Westlake
Lindsay Westlake
2Cancer Program, The Broad Institute of M.I.T. and Harvard, Cambridge, MA USA
2,
Lior Golomb
Lior Golomb
1Department of Medical Oncology, Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA USA
2Cancer Program, The Broad Institute of M.I.T. and Harvard, Cambridge, MA USA
1,2,
Brianna R Silverman
Brianna R Silverman
1Department of Medical Oncology, Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA USA
1,
Myshal D Morris
Myshal D Morris
5Summer Honors Undergraduate Research Program, Harvard Medical School, Boston, MA USA
5,
Ty Running Fisher
Ty Running Fisher
5Summer Honors Undergraduate Research Program, Harvard Medical School, Boston, MA USA
5,
Eden Beyene
Eden Beyene
5Summer Honors Undergraduate Research Program, Harvard Medical School, Boston, MA USA
5,
Yvonne Y Li
Yvonne Y Li
1Department of Medical Oncology, Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA USA
2Cancer Program, The Broad Institute of M.I.T. and Harvard, Cambridge, MA USA
1,2,
Andrew D Cherniack
Andrew D Cherniack
1Department of Medical Oncology, Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA USA
2Cancer Program, The Broad Institute of M.I.T. and Harvard, Cambridge, MA USA
1,2,
Federica Piccioni
Federica Piccioni
3Genetic Perturbation Platform, The Broad Institute of M.I.T. and Harvard, Cambridge, MA USA
12Present Address: Merck Research Laboratories, Cambridge, MA USA
3,12,
J Kevin Hicks
J Kevin Hicks
6Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL USA
6,
Andrew S Chi
Andrew S Chi
7Center for Neuro-Oncology, Division of Neuro-Oncology, Massachusetts General Hospital, Boston, MA USA
7,
Daniel P Cahill
Daniel P Cahill
7Center for Neuro-Oncology, Division of Neuro-Oncology, Massachusetts General Hospital, Boston, MA USA
7,
Jorg Dietrich
Jorg Dietrich
8Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital, Boston, MA USA
8,
Tracy T Batchelor
Tracy T Batchelor
9Department of Neurology, Brigham and Women’s Hospital & Harvard Medical School, Boston, MA USA
9,
David E Root
David E Root
3Genetic Perturbation Platform, The Broad Institute of M.I.T. and Harvard, Cambridge, MA USA
3,
Cory M Johannessen
Cory M Johannessen
2Cancer Program, The Broad Institute of M.I.T. and Harvard, Cambridge, MA USA
13Present Address: Department of Oncology, Novartis Institutes for Biomedical Research, Cambridge, MA USA
2,13,
Matthew Meyerson
Matthew Meyerson
1Department of Medical Oncology, Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA USA
2Cancer Program, The Broad Institute of M.I.T. and Harvard, Cambridge, MA USA
1,2,✉
1Department of Medical Oncology, Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA USA
2Cancer Program, The Broad Institute of M.I.T. and Harvard, Cambridge, MA USA
3Genetic Perturbation Platform, The Broad Institute of M.I.T. and Harvard, Cambridge, MA USA
4Data Science Platform, The Broad Institute of M.I.T. and Harvard Cambridge, Cambridge, MA USA
5Summer Honors Undergraduate Research Program, Harvard Medical School, Boston, MA USA
6Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL USA
7Center for Neuro-Oncology, Division of Neuro-Oncology, Massachusetts General Hospital, Boston, MA USA
8Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital, Boston, MA USA
9Department of Neurology, Brigham and Women’s Hospital & Harvard Medical School, Boston, MA USA
10Present Address: Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA USA
11Present Address: Aera Therapeutics, Cambridge, MA USA
12Present Address: Merck Research Laboratories, Cambridge, MA USA
13Present Address: Department of Oncology, Novartis Institutes for Biomedical Research, Cambridge, MA USA
Subject terms: Cancer genomics, CNS cancer, Non-small-cell lung cancer
© The Author(s) 2024
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
